Dalacin vaginal cream 2% 20g — Made in USA — Free Delivery

the body as a whole - systemic candidiasis, fungal infections, generalized abdominal pain, localized abdominal pain, spastic abdominal pain, headache, pelvic pain, bacterial infections, upper respiratory tract infections, pain throughout the body, back pain, deviations in microbiological tests, allergic reactions;

Gastrointestinal tract - bad breath, diarrhea, nausea, vomiting, constipation, dyspepsia, heartburn, flatulence;

dermatological - itching (not at the injection site), rash, maculopapular rash, erythema, itching (at the injection site), skin candidiasis, urticaria;

Central nervous system - dizziness, headache;

endocrine - hyperthyroidism;

respiratory - nosebleeds;

sense organs - a change in taste.

Suspected Adverse Reactions Report. It is important to be reported on suspected adverse reactions reported after a preparation has been approved. This allows you to continue monitoring the balance of benefits and risks associated with the use of the preparation. Healthcare professionals are asked to report any suspected adverse reactions.

The use of clindamycin can lead to increased growth of resistant microorganisms, in particular yeast.

The use of almost all antibiotics is associated with the occurrence of diarrhea, and in some cases, pseudomembranous colitis. Thus, despite the fact that only a minimal amount of the preparation is absorbed, if severe diarrhea occurs, the preparation should be discontinued and, if necessary, appropriate diagnostic and therapeutic measures should be applied.

Dalacin cream contains carbohydrate-based components. Some of these components have been shown to weaken the rubber material of condoms and contraceptive diaphragms and reduce their effectiveness as a barrier method of contraception or protection against sexually transmitted diseases, including AIDS. During treatment with Dalacin cream, condoms and contraceptive diaphragms should not be used as a means of contraception or protection against diseases.

Pregnancy period. Adequate and properly controlled studies with the participation of women in the first trimester of pregnancy have not been carried out, therefore, the preparation can be used in the first trimester of pregnancy only when essential. In clinical studies with the participation of pregnant women in the second trimester of pregnancy, Dalacin cream was effective in the treatment of bacterial vaginosis and its use was not associated with the occurrence of any negative effects in newborns. However, as before using any other preparation during pregnancy, before prescribing Dalacin cream, it is necessary to carefully weigh the balance of benefits and risks.

Breastfeeding period. It is not known whether clindamycin is excreted in breast milk after intravaginal administration of clindamycin phosphate. However, it has been reported about the penetration of clindamycin into breast milk after oral and parenteral administration, so it is recommended to stop breastfeeding if the preparation is used.

Children. Dalatsin cream is not recommended for use in children under the age of 12 years.

The ability to influence the reaction rate when driving or operating machinery. No data available.

It has been shown that with the simultaneous use of clindamycin with lincomycin, as well as erythromycin with clindamycin, cross-resistance develops. antagonism between clindamycin and erythromycin has been demonstrated in vitro.

It has been shown that clindamycin has the property of blocking neuromuscular transmission and can enhance the action of other neuromuscular blockers. Therefore, it is necessary to use clindamycin with caution in patients taking these blockers.

There is no information regarding the simultaneous use with other intravaginal preparations, therefore such use is not recommended.